2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Monday, November 11, 2019

9:00AM-11:00AM: Abstract Number: 1089

Causes of Death in ANCA-Associated Vasculitis According to ANCA Type

Epidemiology & Public Health Poster II: Spondyloarthritis & Connective Tissue Disease

9:00AM-11:00AM: Abstract Number: 1574

Causes of Death in SLE: Analysis of Inpatient Death from 2000-2018 in a Tertiary Care Hospital in India

SLE – Clinical Poster II: Comorbidities

9:00AM-11:00AM: Abstract Number: 1072

CCR2+ Circulating Monocytes Contribute to the Survival of ADSC in Bleomycin-Induced Skin Fibrosis

Systemic Sclerosis & Related Disorders – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 1064

CD123+ Plasmacytoid Dendritic Cells from Systemic Sclerosis Patients Are Susceptible to the Cytotoxic Activity of Tagraxofusp, a CD123-Targeted Therapy

Systemic Sclerosis & Related Disorders – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 1069

CD4+ T Helper Cell Populations with High PD-1 Expression Are Expanded in Systemic Sclerosis

Systemic Sclerosis & Related Disorders – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 1403

CDAI Analysis of Dose Escalation in a Trial of Infliximab for Rheumatoid Arthritis

RA – Treatments Poster II: Established Treatments

9:00AM-11:00AM: Abstract Number: 1507

Certolizumab Pegol Improves Work and Household Productivity and Social Participation over 1 Year of Treatment in Patients with Non-Radiographic Axial Spondyloarthritis

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Treatment of Axial Spondyloarthritis & Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1508

Certolizumab Pegol-Treated Patients with Non-Radiographic Axial Spondyloarthritis Demonstrate Improvements in Sleep Quality and Other Patient Reported Outcomes

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Treatment of Axial Spondyloarthritis & Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1273

Certolizumab Therapy in Patients with Uveitis During Pregnancy: Multicenter Study

Miscellaneous Rheumatic & Inflammatory Disease Poster II: Autoinflammation Related Diseases & Therapies

9:00AM-11:00AM: Abstract Number: 1641

Change in Calcinosis over 1 Year Using the SCTC Radiologic Scoring System for Calcinosis of the Hands in Patients with Systemic Sclerosis

Systemic Sclerosis & Related Disorders – Clinical Poster II

9:00AM-11:00AM: Abstract Number: 1285

Changes in Nail-fold Capillary Abnormalities, and Serum FGF and VEGF Levels in Dermatomyositis Patients with anti-MDA5 Antibody During the Clinical Course

Muscle Biology, Myositis & Myopathies Poster II

9:00AM-11:00AM: Abstract Number: 1162

Changes in Novel Composite Scores of Disease Activity and Cumulative Damage Are Prognostic of Accelerated Knee Osteoarthritis: Data from the Osteoarthritis Initiative

Imaging Of Rheumatic Diseases Poster II

9:00AM-11:00AM: Abstract Number: 1081

Characteristics of Patients with Seropositive or Seronegative Rheumatoid Arthritis, Psoriatic Arthritis, or Axial Spondyloarthritis: Data from the US-Based Corrona Rheumatoid Arthritis and Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registries

Epidemiology & Public Health Poster II: Spondyloarthritis & Connective Tissue Disease

9:00AM-11:00AM: Abstract Number: 1027

Characterization of Antibody Secreting Cells in Patients with Active Systemic Lupus Erythematosus

SLE – Etiology & Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 1710

Chemokine and Cytokine Tear Profile of Patients with IgG4-Related Disease

Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Behçet’s Disease & Other Vasculitides

«Previous Page
1
…
6
7
8
9
10
…
65
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].